SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0000950142-23-002837
Filing Date
2023-11-24
Accepted
2023-11-24 16:23:24
Documents
2
Group Members
FORESITE CAPITAL FUND V, L.P.FORESITE CAPITAL MANAGEMENT V, LLCFORESITE CAPITAL OPPORTUNITY FUND V, L.P.FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLCJAMES B. TANANBAUM

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 4 eh230423669_13da4-thrx.htm SC 13D/A 111609
2 EXHIBIT 1 eh230423669_ex01.htm EX-99.1 22518
  Complete submission text file 0000950142-23-002837.txt   135881
Mailing Address 314 MAIN STREET, SUITE 04-200 CAMBRIDGE MA 02142
Business Address 314 MAIN STREET, SUITE 04-200 CAMBRIDGE MA 02142 (857) 400-9491
Theseus Pharmaceuticals, Inc. (Subject) CIK: 0001745020 (see all company filings)

IRS No.: 830712806 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-92944 | Film No.: 231436972
SIC: 2834 Pharmaceutical Preparations

Mailing Address 600 MONTGOMERY STREET, SUITE 4500 SAN FRANCISCO CA 94111
Business Address 600 MONTGOMERY STREET, SUITE 4500 SAN FRANCISCO CA 94111 415-877-4887
Foresite Capital Fund V, L.P. (Filed by) CIK: 0001792204 (see all company filings)

IRS No.: 843449937 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A